0818 belimumab (benlysta) (2) · 2020. 9. 3. · recommended dosage for belimumab is 10 mg/kg iv...
TRANSCRIPT
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
(https://www.aetna.com/)
Belimumab (Benlysta)
Clinical Policy Bulletins Medical Clinical Policy Bulletins
Last Review
11/20/2018
Effective: 08/01/2011
Next
Review: 09/10/2020
Review
History
Definitions
Additional Information
Clinical Policy
Bulletin
Notes
Number: 0818
*Please see amendment for Pennsylvania Medicaid at the end of this CPB.
Note: Requires Precertification
Precertification of belimumab (Benlysta) is required of all Aetna participating providers and
members in applicable plan designs. For precertification of belimumab (Benlysta), call (866)
752-7021, or fax (866) 267-3277.
Note: Site of Care Utilization Management Policy applies to belimumab (Benlysta). For
information on site of service for Benlysta infusions, see
Utilization Management Policy on Site of Care for Specialty Drug Infusions
(https://www.aetna.com/health-care-professionals/utilization-management/drug-infusion
site-of-care-policy.html)
.
Aetna considers belimumab (Benlysta) medically necessary for the treatment of active systemic
lupus erythematosus (SLE) when all of the following criteria are met (see below: Exclusion
Criteria for Belimumab):
Prior to initiating therapy, the member is positive for autoantibodies relevant to SLE (e.g.,
anti-nuclear antibody or anti-double-stranded DNA antibody), and
The member is receiving standard treatment for SLE with any of the following (alone or
in combination):
Proprietary 1/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
Glucocorticoids (e.g., prednisone, methylprednisolone, dexamethasone)
Antimalarials (e.g., hydroxychloroquine)
Immunosuppressants (e.g., azathioprine, methotrexate, mycophenolate,
cyclosporine, cyclophosphamide).
Aetna considers continuation of belimumab medically necessary for all members (including new
members) who are using belimumab for an indication outlined above and who achieve or
maintain a positive clinical response as evidenced by low disease activity or improvement in
signs and symptoms of the condition.
Exclusion Criteria for Belimumab
Benlimumab is considered experimental and investigational for persons with the following:
Severe active lupus nephritis (proteinuria greater than 6 g/24 hours or equivalent using
spot urine protein to creatinine ratio, or serum creatinine greater than 2.5 mg/dl)
Severe active central nervous system lupus (including seizures, psychosis, organic brain
syndrome, cerebrovascular accident, cerebritis, or CNS vasculitis requiring therapeutic
intervention within 60 days before initiation of belimumab)
Member is using belimumab in combination with other biologics or intravenous
cyclophosphamide.
Experimental and Investigational
Aetna considers belimumab experimental and investigational for all other indications
including the following (not an all-inclusive list) because its effectiveness for indications other
than the one listed above has not been established:
Antibody-associated vasculitis
Antibody-mediated rejection in lung transplantation and kidney transplantation
Anti-phospholipid antibody syndrome
Gout
Immunosuppressionfollowingstemcell/solidorgantransplantations
Multiple sclerosis
Myasthenia gravis
Psoriatic arthritis
Retinal vasculitis
Rheumatoid arthritis
Proprietary 2/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
Sjogren syndrome
Systemic sclerosis
Uveitis
Waldenstrom macroglobulinemia
Systemic Lupus Erythematosus (SLE):
Intravenous infusion: Benlysta (belimumab) is available as 120 mg or 400mg lyophilized
powder in single-dose vials for reconstitution and dilution prior to IV infusion. The
recommended dosage for belimumab is 10 mg/kg IV over 1 hour every 2 weeks for the
first 3 doses then every 4 weeks thereafter.
Subcutaneous injection: Benlysta (belimumab) is available as a 200 mg/mL single-dose
prefilled autoinjector or single-dose prefilled syringe. The recommended dosage for
subcutaneous belimumab is 200 mg once weekly. Note: subcutaneous dosing of
Benlysta has not been evaluated and is not approved for members younger than 18
years of age.
Source: GlaxoSmithKline, 2019
Benlysta (belimumab) is a human monoclonal antibody drug that specifically recognizes and
inhibits the biological activity of B‐lymphocyte stimulator, or BLyS. BLyS is a cytokine that
belongs to the tumor necrosis factor (TNF) ligand family. It is expressed as transmembrane
protein on various cell types including monocytes, dendritic cells, and bone marrow stromal cells
and is required for the development of B‐lymphocyte cells into mature plasma B cells. Plasma B
cells produce anti‐bodies, the body's first line of defense against infection. In lupus and certain
other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production
of autoantibodies –antibodies that attack and destroy the body's own healthy tissues. The
presence of autoantibodies appears to correlate with disease severity. Preclinical and clinical
studies suggest that belimumab can reduce autoantibody levels inSLE.
Proprietary 3/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
Benlysta (belimumab) has been approved by the U.S. Food and Drug Administration (FDA) for
the adjunctive treatment of active, autoantibody-positive, systemic lupus erythematosus (SLE).
Belimumab has not been evaluated and is not recommended in patients with severe active lupus
nephritis or severe active central nervous system lupus or in combination with other biologic
products or cyclophosphamide.
Systemic lupus erythematosus (SLE) is a potentially fatal, autoimmune disease, which is
characterized by clinical diversity, alerations in the disease activity over time, and aberrations in
multiple components of the immune system including B cells, T cells, as well as cytokines and
growth factors, especially the presence of anti-nuclear antibodies (ANA) that are found in over 90
% of the patients. Moreover, anti-double-strand deoxyribonucleic acid (anti-dsDNA) antibodies
are found in 50 to 90 % of the patients. The prevalence of SLE worldwide is 4 to 250 per
100,000; the disease affects women disproportionately (approximately 90 % of the patients are
female). The incidence is most frequent in women aged 15 to 25 years. The disease affects
many parts of the body including the brain, heart, joints, kidneys, lungs, and the skin. When SLE
flares, it can present as chest pain, fatigue, fever, hair loss, rash, light sensitivity, as well as
swelling in the joints and joint pain (Finnish Medical Society,2007).
Conventional treatments of SLE include anti-malarials (e.g., chloroquine and
hydroxychloroquine), corticosteroids, and non-steroidal anti-inflammatory drugs (e.g., aspirin).
While therapeutic advances in immunosuppressive drugs (e.g., azathioprine, cyclophosphamide,
methotrexate, mycophenolate) and support therapy have markedly improved survival, SLE still
carries substantially increased rates of mortality and end stage renal disease, which are even
more elevated in younger patients. No new drugs have been approved for SLE in over 50
years. Hence, a lot of hope and excitement has been generated by the development of
biological agents designed to eliminate B cells either through direct killing (anti-B cell antibodies
such as rituximab) or attrition by inhibition of survival (anti-B-lymphocyte stimulator BLyS [also
known asBAFF] agents such as belimumab). Belimumab is a human IgG1g antibody that is the
first of the BLyS-specific inhibitor. It blocks the binding of soluble BLyS, a B-cell survival factor,
to its receptors on B cells. Belimumab does not bind B cells directly, but by binding BLyS,
belimumab inhibits the survival of B cells, including auto-reactive B cells, and reduces the
differentiation of B cells into immunoglobulin-producing plasma cells. Clinical trials of various
phases have indicated that belimumab is beneficial for patients with SLE (Furie et al, 2008;
Wallace et al, 2009; Jacobi et al, 2010; Navarra et al,2011).
In a phase I clinical study, Furie et al (2008) evaluated the safety, biological activity, and
pharmacokinetics of belimumab in patients with SLE. A total of 70 patients with mild-to-
moderate SLE were randomized to receive placebo (n = 13) or belimumab (n = 57) at 4 different
doses (1.0, 4.0, 10, and 20 mg/kg body weight) as a single infusion or two infusions 21 days
Proprietary 4/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
apart. Patients were followed for 84 to 105 days to assess adverse events, pharmacokinetics,
peripheral blood B-cell counts, serology, and SLE disease activity. Data from the study were
summarized using descriptive statistics. Chi-square type tests were used to analyze discrete
variables. The Kruskal-Wallis test, the Wilcoxon test, and the analysis of co-variance were used
to analyze the continuous variables, as appropriate. The analysis was performed on all
randomized patients who received study agent. The incidences of adverse events and
laboratory abnormalities were similar among the belimumab and placebo groups. Belimumab
pharmacokinetics were linear across the 1.0 to 20 mg/kg dose range. Long terminal elimination
half-life (8.5 to 14.1 days), slow clearance (7 ml/day per kg), and small volume of distribution (69
to 112 ml/kg) were consistent with a fully human antibody. Significant reductions in median
percentages of CD20+ B cells were observed in patients treated with a single dose of belimumab
versus placebo (day 42: p = 0.0042; and day 84: p = 0.0036) and in patients treated with 2 doses
of belimumab versus placebo (day 105: p = 0.0305); SLE disease activity did not change after 1
or 2 doses of belimumab. The authors concluded that belimumab was well-tolerated and
reduced peripheral B-cell levels in SLE patients.
In a phase II, randomized, double-blind, placebo-controlled, dose-ranging study, Wallace and
colleagues (2009) evaluated the safety, tolerability, biological activity, and effectiveness of
belimumab in combination with standard of care therapy (SOC) in patients with active SLE.
Patients with a Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA)
version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score greater
than or equal to 4 (n = 449) were randomly assigned to belimumab (1, 4, or 10 mg/kg) or placebo
in a 52-week study. Co-primary end points were the percent change in the SELENA-SLEDAI
score at week 24 and the time to first SLE flare. Significant differences between the treatment
and placebo groups were not attained for either primary end point, and no dose response was
observed. Reductions in SELENA-SLEDAI scores from baseline were 19.5 % in the combined
belimumab group versus 17.2 % in the placebo group. The median time to first SLE flare was 67
days in the combined belimumab group versus 83 days in the placebo group. However, the
median time to first SLE flare during weeks 24 to 52 was significantly longer with belimumab
treatment (154 versus 108 days; p = 0.0361). In the subgroup (71.5 %) of serologically active
patients (ANA titer greater than or equal to 1:80 and/or anti-dsDNA greater than or equal to 30
International Units/ml), belimumab treatment resulted in significantly better responses at week 52
than placebo for SELENA-SLEDAI score (-28.8 % versus -14.2 %; p = 0.0435), physician's
global assessment (-32.7 % versus -10.7 %; p = 0.0011), and Short Form-36 physical
component score (+3.0 versus +1.2 points; p = 0.0410). Treatment with belimumab resulted in a
63 to 71 % reduction of naive, activated, and plasmacytoid CD20+ B cells, and a 29.4 %
reduction in anti-dsDNA titers (p = 0.0017) by week 52. The rates of adverse events and serious
adverse events were similar in the belimumab and placebo groups. The authors concluded that
Proprietary 5/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
belimumab was biologically active and well-tolerated. The effect of belimumab on the reduction
of SLE disease activity or flares was not significant. However, serologically active SLE patients
responded significantly better to belimumab therapy plus SOC than to SOC alone.
Jacobi and co-workers (2010) examined the effects of long-term BLyS inhibition in patients with
SLE. A total of 17 subjects with SLE who were enrolled in a clinical trial of belimumab plus SOC
were studied. Phenotypic analysis of lymphocytes was performed using flowcytometry.
Circulating antibody-secreting cells were enumerated using enzyme-linked immunospot assay.
Serum was analyzed by enzyme-linked immunosorbent assay using an antibody that recognizes
products of the V(H)4-34 gene. Lymphocyte counts, Ig levels, and anti-dsDNA antibody levels
were available as part of the clinical trial analyses. Samples were collected on days 0, 84, 168,
365, and 532 and after day 730. The total number of B cells started to decrease from baseline
between days 84 and 168. This was due to a decrease in naive and transitional B cells.
CD27+IgD+ memory B cells and plasmablasts decreased only after 532 days, whereas
CD27+IgD- memory B cells were not affected, and there were no changes in T cells. Serum IgM
levels began to decline between days 84 and 168, but there were no changes in serum levels of
IgG, IgG anti-DNA antibodies, or V(H)4-34 antibodies during the study. Patients with SLE had
more IgM-, IgG-, and autoantibody-producing B cells than did normal controls on day 0. There
was only a modest decrease in the frequency of total IgM-producing, but not IgG-producing, cells
on days 365 and 532, consistent with the phenotypic and serologic data. The authors concluded
that these findings confirm the dependence of newly formed B cells on BLyS for survival in
humans. In contrast, memory B cells and plasma cells are less susceptible to selective BLyS
inhibition.
In a randomized, multi-center, placebo-controlled, phase III trial, Navarra and associates (2011)
evaluated the safety and effectiveness of belimumab in patients with active SLE. Patients (aged
greater than or equal to 18 years) who were sero-positive with scores of at least 6 on the
SELENA-SLEDAI were enrolled in the study. Patients were randomly assigned by use of a
central interactive voice response system in a 1:1:1 ratio to belimumab 1 mg/kg or 10 mg/kg, or
placebo by intravenous infusion in 1 hr on days 0, 14, and 28, and then every 28 days until 48
weeks, with SOC. Patients, investigators, study coordinators, and sponsors were masked to
treatment assignment. Primary efficacy end point was improvement in the SLE Responder Index
(SRI) at week 52 (reduction greater than or equal to 4 points in SELENA-SLEDAI score; no new
British Isles Lupus Assessment Group [BILAG] A organ domain score and no more than 1 new B
organ domain score; and no worsening [less than 0·3 increase] in Physician's Global
Assessment [PGA] score) versus baseline. Method of analysis was by modified intention-to-
treat. A total of 867 patients were randomly assigned to belimumab 1 mg/kg (n = 289) or 10
mg/kg (n = 290), or placebo (n = 288); 865 were treated and analyzed in the belimumab (1
mg/kg, n = 288; 10 mg/kg, n = 290) and placebo groups (n = 287). Significantly higher SRI rates
Proprietary 6/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
were noted with belimumab 1 mg/kg (148 [51 %], odds ratio 1.55 [95 % confidence interval [CI]:
1.10 to 2.19]; p = 0·0129) and 10 mg/kg (167 [58 %], 1.83 [1.30 to 2.59]; p = 0·0006) than with
placebo (125 [44 %]) at week 52. More patients had their SELENA-SLEDAI score reduced by at
least 4 points during 52 weeks with belimumab 1 mg/kg (153 [53 %], 1.51 [1.07 to 2.14]; p =
0·0189) and 10 mg/kg (169 [58 %], 1.71 [1.21 to 2.41]; p = 0·0024) than with placebo (132 [46
%]). More patients given belimumab 1 mg/kg (226 [78 %], 1.38 [0.93 to 2.04]; p = 0·1064) and
10 mg/kg (236 [81 %], 1.62 [1.09 to 2.42]; p = 0·0181) had no new BILAG A or no more than 1
new B flare than did those in the placebo group (210 [73 %]). No worsening in PGA score was
noted in more patients with belimumab 1 mg/kg (227 [79 %], 1.68 [1.15 to 2.47]; p = 0·0078) and
10 mg/kg (231 [80 %], 1.74 [1.18 to 2.55]; p = 0·0048) than with placebo (199 [69 %]). Rates of
adverse events were similar in the groups given belimumab 1 mg/kg and 10 mg/kg, and placebo:
serious infection was reported in 22 (8 %), 13 (4 %), and 17 (6 %) patients, respectively, and
severe or serious hypersensitivity reactions on an infusion day were reported in 2 (less than 1
%), 2 (less than 1 %), and no patients, respectively. No malignant diseases were reported. The
authors concluded that belimumab has the potential to be the first targeted biological treatment
that is approved specifically for SLE, providing a new option for the management of this
important prototypic autoimmune disease.
On March 8, 2011, the U.S. Food and Drug Administration approved belimumab (Benlysta) for
the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus
who are receiving standard therapy, including anti-malarials, corticosteroids,
immunosuppressives, and non-steroidal anti-inflammatory drugs. The label for Benlysta includes
the following limitations of use: The efficacy of belimumab has not been evaluated in patients
with severe active lupus nephritis or severe active central nervous system lupus, and has not
been studied in combination with other biologics or intravenous cyclophosphamide. Belimumab
is administered intravenously over a 1-hour period; it should not be administered with live
vaccines. The most common side effects associated with the use of belimumab include
diarrhea, fever, and nausea. Patients also commonly experienced infusion reactions; thus, pre-
treatment with an anti-histamine should be considered. Belimumab is approved at a dosage of
10 mg/kg of body weight to be given at 2-week intervals for the first 3 doses and 4-week intervals
thereafter. In several randomized controlled trials examining the effectiveness of belimumab in
patients with SLE, the durations of therapy were 52 and 76 weeks (Phung, 2011). In a clinical
study of belimumab submitted to the FDA for approval, active SLE disease was defined as a
SELENA-SLEDAI (Safety of Estrogens in Lupus Erythematosus: National Assessment-Systemic
Lupus Erythematosus Disease Activity Index) score of equal to or greater than 4, and positive
autoantibody test results (anti-nuclear antibody [ANA] and/or anti-double-stranded DNA [anti-
dsDNA]) at screening.
Proprietary 7/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
Belimumab has also been studied in the treatment of other autoimmune diseases such as lupus
nephritis, multiple sclerosis, and rheumatoid arthritis (Aran and Putterman, 2008; Hawker, 2008;
Bingham, 2008). Furthermore, belimumab is being considered as one of the novel strategies in
immunosuppression following stem cell/solid organ transplantations (Webber et al, 2011).
However, in the absence of evidence based on large, randomized, placebo-controlled trials, the
role of belimumab for these indications has yet to beestablished.
The American College of Rheumatology's guidelines for screening, treatment, and management
of lupus nephritis (Hahn et al, 2012) notes that alternative therapies (e.g., rituximab, tacrolimus,
belimumab, calcineurin inhibitors) were considered but no consensus for recommendation was
reached.
Khattri and colleagues (2012) stated that the increased awareness of the role of humoral
immunophysiology in anti-phospholipid syndrome (APS) has aroused interest in B cells as
therapeutic targets in this disease. These researchers reviewed the literature on B cell-directed
therapies in human and experimental APS. The clinical data were limited to B cell depletion with
rituximab and comprised case reports and case series. Murine studies include use of
modulators of B cell function (e.g., belimumab and abatacept). In both human and murine
studies, B cell-directed therapies appeared to have clinical and serologic beneficial effects
including a decrease in the anti-phospholipid antibody titers after treatment. The authors
concluded that randomized controlled trials are needed to examine if B cell depletors and/or B
cell modulators can be effective agents for treating patients with APS.
O'Neill and Scully (2013) noted that biologic therapy has a potential to benefit patients with
orofacial manifestations of Sjogren syndrome (SS). The most appropriate use of biologics would
appear to be in patients with severe or multi-system features of SS, but their use early in the
pathogenesis has the potential to prevent disease progression. Tumor necrosis factor-alpha
blockade has not proven effective in SS. B-cell depletion using rituximab has been of benefit,
mainly in relation to extra-glandular features, and to some extent in relation to hypo-salivation
where there is still residual salivary function. Rituximab is also effective in the treatment of SS-
associated (extra-salivary) lymphomas, although the therapeutic response in salivary lymphoma
is poorer. Rituximab is given as a single or periodic intravenous infusion. Potential adverse
effects exist, notably infusion reactions and infection, and so a full risk/benefit analysis is
indicated for prospective patients. The authors concluded that further studies of rituximab in SS
are ongoing, and newer agents under trial include belimumab.
Jin and Ding (2013) summarized up-to-date pharmacological and clinical data of belimumab in
the treatment of rheumatoid arthritis (RA). A literature search was performed on PubMed using
keywords, including belimumab, LymphoStat-B, benlysta, BLyS inhibitor, rheumatoid arthritis and
Proprietary 8/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
autoimmune disease. References of relevant studies were searched by hand. Abstracts of
international conferences up to October 2012 were also included. Belimumab was well-tolerated
in the treatment of RA over 24 weeks. It significantly increased American College of
Rheumatology (ACR)20 responses at week 24, especially in patients with high disease activity,
positive rheumatoid factor, no anti-tumor necrosis factor (TNF) treatment experience and those
who had failed methotrexate therapy. However, belimumab failed to demonstrate significantly
improved ACR50 and ACR70 responses in the single phase II clinical trial of RA. The authors
concluded that these results suggested that the clinical effectiveness of belimumab for RA needs
to be further investigated in future clinical trials. Careful patient selection may be necessary for
belimumab to achieve optimal clinical outcomes in RA.
In a single-arm, phase II clinical trial, Bishton et al (2013) evaluated the safety and activity of
belimumab in 12 patients with Waldenstrom macroglobulinemia (WM). A total of 10 patients had
stable disease with therapy, although no objective responses were seen. Correlative studies
showed patients to have low or undetectable baseline serum levels of B-lymphocyte stimulator,
with the administration of belimumab having no effect on B-cell numbers. The authors concluded
that belimumab cannot be recommended as a single-agent therapy for the treatment of
symptomatic WM, although further evaluation in combination with other agents would be
justified.
Furuta and Jayne (2014) noted that the current standard therapy for anti-neutrophil cytoplasm
antibody-associated vasculitis (AAV), high-dose glucocorticoid and cyclophosphamide followed
by azathioprine, has improved the disease prognosis. However, there are still unmet needs. For
example, reducing relapse risk and glucocorticoid toxicity; newer therapies are needed. These
researchers stated that potential newer drugs are emerging following a better understanding of
disease mechanisms and the availability of targeted therapies to B cells, T cells, pro-
inflammatory cytokines and complement. Rituximab has proven efficacy in remission induction
therapy for AAV, and 2 trials with rituximab as remission maintenance therapy are ongoing.
Clinical trials evaluating mycophenolate mofetil as remission induction therapy, gusperimus,
belimumab and complement factor C5a inhibition are also ongoing, and many other potential
candidates are being investigated both clinically and experimentally. The authors concluded that
B-cell therapy is now an established treatment in AAV and several other therapies are under
evaluation. However, the unmet need in vasculitis therapy remains large and newer therapies
either alone or in combination will need to both improve efficacy and permit reductions in
glucocorticoid and immunosuppressive exposure.
Schwartz et al (2014) stated that renal involvement is a major cause of morbidity and mortality in
SLE. These researchers provided an update on recent discoveries in the pathogenesis,
diagnosis, and treatment of lupus nephritis. Localized long-lived plasma cells have been
Proprietary 9/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
identified as playing an important role in lupus nephritis. In addition, the roles of aberrant
expression of microRNAs and pro-inflammatory cytokines have been explored. Early diagnosis
is important for effective treatment and multiple biomarkers have been identified; however, none
has been yet validated for clinical use. Biomarker panels may turn out to be more accurate than
each individual component. Biologic agents for the treatment of lupus nephritis are being
studied, including belimumab which was recently approved for non-renal SLE. Rituximab has
not proven itself in large, placebo-controlled trials, although it is still being used in refractory
cases of lupus nephritis. The authors concluded that lupus nephritis is a potentially devastating
complication of SLE. Immune cells, cytokines, and epigenetic factors have all been recently
implicated in lupus nephritis pathogenesis. These recent discoveries may enable a paradigm
shift in the treatment of this complex disease, allowing the tailoring of treatment to target specific
pathogenic mediators at specific points in time in the progression of disease.
In a review on “The future of uveitis treatment”, Lin and colleagues (2014) listed belimumab as
one of the emerging therapies for the treatment of uveitis. Furthermore, an UpToDate review on
“Uveitis: Treatment” (Rosenbaum, 2014) does not mention belimumab as a therapeutic option.
Selmi and colleagues (2014) stated that as the understanding of the pathogenesis of
autoimmune diseases is growing, new therapies are being developed to target disease-specific
pathways. Since the introduction of etanercept in 1998, several biotechnological agents have
been developed, most of them indicated in the treatment of RA, but also psoriatic arthritis. Most
currently available molecules target TNF-alpha with different strategies (i.e., etanercept,
infliximab, adalimumab, golimumab, and certolizumab pegol), interleukin (IL)-6 (tocilizumab),
CTLA-4 (abatacept), and B cells (rituximab, belimumab) as they are key mediators in the
cascade of inflammation. Further, small molecules have been recently developed to target intra-
cellular signaling, such as janus kinases for tofacitinib, the first FDA-approved small molecule for
RA. Most novel treatments are being developed for arthritis with specific differences between RA
and psoriatic arthritis, as well as for SLE, following the approval of belimumab. Finally, biologic
therapies are effective also in gout, mainly targeting IL-1 to block the inflammasome. These
researchers described the new and upcoming treatment options for RA, psoriatic arthritis, SLE,
and gout to dissect what one should be aware of when discussing these new and promising
molecules.
In a phase II clinical trial, De Vita and colleagues (2015) examined the safety and effectiveness
of long-term treatment of SS with belimumab. Patients with primary SS were included in the
BELISS study, a 1-year open-label trial, if they were positive for anti-SSA or anti-SSB antibodies
and had systemic complications or persistent salivary gland enlargement or early disease or
biomarkers of B-cell activation. They received intravenous belimumab, 10 mg/kg, at weeks 0, 2
and 4 and then every 4 weeks; if response was observed at week 28, or if the clinician and the
Proprietary 10/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
patient agreed to continue the study in the absence of side effects, treatment was continued for 1
year. Safety and effectiveness were analyzed during the 1-year period of treatment. Among the
30 patients recruited, 28 were evaluated at week 28 as already reported; 19 terminated the 52-
week study, 15 of them being responders and 4 non-responders at week 28; 13 of the 15
responders at week 28 also responded at week 52 (86.7 %). The improvement in the EULAR
Sjogren's Syndrome Disease Activity Index and EULAR Sjogren's Syndrome Patient Reported
Index scores observed at week 28 showed a trend to further improvement at week 52, and the
amelioration of peculiar EULAR Sjogren's Syndrome Disease Activity Index domains (glandular,
lymphadenopathy, articular) appeared of particular relevance. The decrease in biomarkers of B-
cell activation observed at week 28 persisted unchanged until week 52, with RF decreasing
further. Salivary flow, Schirmer's test and the focus score of salivary biopsy did not change.
Safety of treatment was good. The authors concluded that long-term treatment with belimumab
may be beneficial in SS; randomized, double-blind, controlled studies in larger populations are
encouraged.
In April 2019, Benlysta, for intravenous use, was FDA-approved for use in pediatric patients
aged 5 years and older with active, autoantibody positive, systemic lupus erythematosus (SLE)
who are receiving standard therapy. (GSK, 2019).
Sjogren's Syndrome
Mariette et al (2015) evaluated the safety and effectiveness of belimumab in patients with
primary Sjogren's syndrome (pSS). Patients were included in this bi-centric prospective 1-year
open-label trial if they fulfilled American European Consensus group criteria, were anti-Sjogren's
syndrome A-positive and had current systemic complications or salivary gland enlargement, or
early disease (less than 5 years), or biomarkers of B cell activation. They received belimumab,
10 mg/kg, at weeks 0, 2 and 4 and then every 4 weeks to week 24. The primary end-point,
assessed at week 28, was improvement in 2 of 5 items: reduction in greater than or equal to 30
% in dryness score on a visual analog scale (VAS), greater than or equal to 30 % in fatigue VAS
score, greater than or equal to 30 % in VAS pain score, greater than or equal to 30 % in systemic
activity VAS assessed by the physician and/or greater than 25 % improvement in any B cell
activation biomarker values. Among 30 patients included, the primary end-point was achieved in
18 (60 %). The mean (SD) European League Against Rheumatism (EULAR) Sjogren's
Syndrome Disease Activity Index decreased from 8.8 (7.4) to 6.3 (6.6) (p = 0.0015) and EULAR)
Sjogren's Syndrome Patient Reported Index from 6.4 (1.1) to 5.6 (2.0) (p = 0.0174). The mean
dryness, fatigue and pain VAS varied from 7.8 (1.8) to 6.2 (2.9) (p = 0.0021), 6.9 (1.8) to 6.0 (2.2)
(p = 0.0606) and 4.6 (2.6) to 4.7 (2.4) (p = 0.89), respectively. Salivary flow and Schirmer's test
Proprietary 11/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
did not change. The authors concluded that these encouraging results justified future
randomized controlled trials of belimumab in a selected target population of pSS patients most
likely to benefit from treatment.
In a systematic review and meta-analysis, Letaief and colleagues (2018) examined the clinical
safety and effectiveness of B-cell targeted therapies for pSS. These investigators performed a
systematic literature review using databases including Medline, Embase and Cochrane. Only
articles reporting controlled or prospective studies of biological disease-modifying anti-rheumatic
drugs (b-DMARDs) modulating B cells in treatment of pSS were selected. The highest-quality
studies were selected for meta-analysis. The primary outcome of interest was clinical efficacy at
week 24 on fatigue, dryness, Schirmer test, salivary flow rate and the full EULAR Sjogren's
syndrome disease activity index (ESSDAI) score including biological domain. For the efficacy
criteria used, the difference between rituximab and placebo groups was expressed as mean
difference (MD). A total of 18 articles (13 of rituximab, 3 of belimumab, 1 of epratuzumab and 1
of baminercept) were identified for detailed evaluation; 4 randomized controlled trials (RCTs) of
rituximab treatment versus placebo involving 300 patients were included for quantitative
analysis. No significant differences were observed between groups in the meta-analysis of mean
improvements between baseline and week 24 in fatigue VAS [MD -3,24 95 % CI: -30,21 to
23.72], oral dryness VAS [MD -8.41 95 % CI: -35.06 to 18.24], salivary flow rate [MD 0.04 95 %
CI: -0.03 to 0.11] and Schirmer test [MD 0.35 95 % CI: -2.13 to 2.82)]. Rituximab was relatively
safe compared to placebo. The authors concluded that the findings of this review showed that
rituximab is not effective in pSS with the designs and outcomes proposed in the trials; RCTs are
needed to prove the effectiveness of belimumab and epratuzumab in this indication. The RCT
evaluating baminercept failed to achieve its primary end-point.
Cutaneous Lupus
Vashisht and colleagues (2017) presented their experience of using belimumab for the
management of cutaneous lupus at their center. These researchers studied 5 patients with
significant SLE skin manifestations. All patients met 1997 ACR SLE criteria and had failed
multiple medications to control their skin disease; PGA, SLEDAI, and Cutaneous LE disease
Area and Severity Index (CLASI) were recorded before and 16 weeks after belimumab
treatment. Belimumab was added to concomitant standard therapy. All 5 patients demonstrated
marked clinical improvement following belimumab treatment. The average time to clinical
improvement after treatment initiation was 8 to 12 weeks; SLEDAI scores (median, range)
improved in all the patients ((2, 2 to 6) to (0, 0 to 4); p = 0.025); PGA scores (median, range)
were better in all patients ((3, 2 to 3) to (1, 0 to 1); p = 0.039); CLASI activity scores (median,
range) improved dramatically in all patients ((17, 9 to 31) to (3, 2 to 14); p = 0.043). There was
no worsening of the CLASI damage scores. The mean daily prednisone dose decreased
Proprietary 12/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
significantly from 31 mg (± 18.8) at baseline to 3 mg (± 2.7) (p = 0.042). The authors concluded
that in this case series, the addition of belimumab to standard therapy improved the signs and
symptoms of refractory cutaneous lupus. This was one of the first reports highlighting the
potential utility of this medication for the treatment of severe skin involvement in SLE refractory
to conventional therapies. Moreover, they stated that additional studies are needed to evaluate
the use of belimumab in the treatment of cutaneous lupus.
Retinal Vasculitis
De Scheerder and colleagues (2016) reported the case of a 26-year old African female who was
treated successfully with belimumab in a case of severe membranous lupus nephritis and retinal
vasculitis, resistant to 1st line therapy. She presented initially with chronic dacryoadenitis and
screening showed nephrotic-range proteinuria. Biopsy of the kidney confirmed the diagnosis of
membranous lupus nephritis. Clinical features (joint pain, dacryoadenitis, retinal vasculitis and
lupus nephritis) in combination with serology (positive anti-double-stranded DNA (ds-DNA)
antibodies, hypocomplementemia) confirmed the diagnosis of SLE. Treatment was immediately
initiated with glucocorticosteroids (GCS), mycophenolate mofetil (MMF) and hydroxychloroquine
sulphate (Plaquenil). Tacrolimus was associated but no effect was observed with the proteinuria
remaining in the nephrotic range and secondary effects of the glucocorticoids becoming a real
concern. The patient was started on add-on belimumab with quasi-immediate effect on the
proteinuria, making it possible to decrease the dosage of the other immunosuppressants and
gradually stop them, even the GCS. The patient is currently in complete remission after 3 years
of treatment with belimumab. The authors were able to stop immunosuppressive treatment but
kept the patient on anti-malarial treatment as the most recent guidelines in treatment of SLE
recommend. This was a single-case study; its findings need to be validated by well-designed
studies.
Myasthenia Gravis
Diaz-Manera et al (2012) stated that new treatments for immune mediated diseases have
increased notably in the last 10 years. Monoclonal antibodies directed against different
components of the immune system have appeared, along with new drugs from the hematology
field. In the case of myasthenia gravis (MG), many of these new treatments have been used in
experimental animal models and also in patients. These investigators reviewed the progress in
the field of MG treatment achieved in the last 5 years. Firstly, the current treatment protocol was
introduced. Secondly, new data from recent randomized trials and case series of patients
treated with methotrexate, cyclophosphamide, rituximab or improved systems of apheresis was
reported. Finally, all future treatments that are currently under evaluation in pre-clinical animal
models of experimental autoimmune MG were discussed. Evidence supporting the use of
Proprietary 13/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
methotrexate and rituximab in MG has been published recently, in addition to conflicting
randomized trials that were not successful, evaluating the use of tacrolimus as a steroid sparing
agent. New promising therapies (e.g., belimumab and eculizumab) are currently under
evaluation in clinical trials.
In a phase-II, multi-center, placebo-controlled, double-blind study, Hewett and colleagues (2018)
examined the safety and efficacy of belimumab in patients with generalized MG who remained
symptomatic despite standard of care (SoC) therapy. Eligible participants with MG were
randomized 1:1 to receive IV belimumab 10 mg/kg or placebo. Participants received SoC
therapies throughout the 24-week treatment phase and 12-week follow-up period. The primary
efficacy end-point was mean change from baseline in the Quantitative Myasthenia Gravis (QMG)
scale at week 24; safety assessments included the frequency and severity of adverse events
(AEs) and serious AEs. A total of 40 subjects were randomized (placebo n = 22; belimumab n =
18). The mean change in QMG score from baseline at week 24 was not significantly different for
belimumab versus placebo (p = 0.256). There were no statistically significant differences
between treatment groups for secondary end-points, including the MG Composite and MG-
Activity of Daily Living scores. Acetylcholine receptor antibody levels decreased over time in
both treatment groups. No unexpected AEs were identified and occurrence was similar in the
belimumab (78 %) and placebo (91 %) groups; 1 subject receiving placebo died (severe sepsis)
during the treatment phase. The authors concluded that the primary end-point was not met for
belimumab in participants with generalized MG receiving SoC. There was no significant
difference in mean change in the QMG score at week 24 for belimumab versus placebo. The
safety profile of belimumab was consistent with previous SLE studies. This study provided Class
I evidence that for participants with generalized MG, belimumab did not significantly improve
QMG score compared with placebo.
Antibody-Mediated Rejection in Lung Transplantation
Hulbert and colleagues (2018) stated that there is increasing recognition of the importance of
antibody-mediated rejection (AMR) after lung transplantation. The development of donor-specific
antibodies, a key feature of AMR, occurs in approximately 30 % of lung transplant recipients and
is associated with poor post-transplant outcomes. These investigators high-lighted recently
developed AMR diagnostic criteria in lung transplantation, potential mechanisms that mediate
the development of AMR, and discusses current and emerging treatment strategies for this
significant, graft-limiting complication. A major advance is the development of consensus
guidelines to precisely define AMR among lung transplant. Regimens for the treatment of AMR
continue to evolve with varying success reported with regards to antibody clearance and
improving clinical outcomes. A multi-modality treatment approach was common, typically
involving a combination of intravenous immune globulin (IVIG), plasmapheresis (PP), rituximab,
Proprietary 14/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
and bortezomib or carfilzomib. The authors concluded that recent studies suggested several
new agents including tocilizumab, belimumab, daratumumab, plerixafor, and C1 esterase
inhibitor as potentially novel and effective therapies to employ in AMR treatment. These
investigators noted that despite advancements in the diagnosis of AMR through well-defined
consensus guidelines, there is limited evidence to guide treatment. Current data suggests that
conventional approaches are of sub-optimal efficacy, but emerging therapeutic agents with
diverse biological mechanisms offer promise for improved AMR treatment.
Antibody-Mediated Rejection in Kidney Transplantation
Banham and colleagues (2018) stated that B cells produce allo-antibodies and activate allo-
reactive T cells, negatively affecting kidney transplant survival. By contrast, regulatory B cells
are associated with transplant tolerance. Immunotherapies are needed that inhibit B-cell effector
function, including antibody secretion, while sparing regulators and minimizing infection risk. B
lymphocyte stimulator (BLyS) is a cytokine that promotes B-cell activation and has not previously
been targeted in kidney transplant recipients. These researchers examined the safety and
activity of an anti-BLyS antibody, belimumab, in addition to standard-of-care immunosuppression
in adult kidney transplant recipients. They used an experimental medicine study design with
multiple secondary and exploratory end-points to gain further insight into the effect of belimumab
on the generation of de-novo IgG and on the regulatory B-cell compartment. In a randomized,
double-blind, placebo-controlled, phase-II clinical trial, these researchers employed belimumab,
in addition to standard-of-care immunosuppression (basiliximab, mycophenolate mofetil,
tacrolimus, and prednisolone) at 2 centers. Subjects were eligible if they were aged 18 to 75
years and receiving a kidney transplant and were planned to receive standard-of-care
immunosuppression. They were randomly assigned (1:1) to receive either intravenous
belimumab 10 mg/kg body weight or placebo, given at day 0, 14, and 28, and then every 4
weeks for a total of 7 infusions. The co-primary end-points were safety and change in the
concentration of naive B cells from baseline to week 24, both of which were analyzed in all
patients who received a transplant and at least 1 dose of drug or placebo (the modified intention-
to-treat [mITT] population). Between September 13, 2013, and February 8, 2015, of 303 patients
assessed for eligibility, 28 kidney transplant recipients were randomly assigned to receive
belimumab (n = 14) or placebo (n = 14); 25 patients (12 [86 %] patients assigned to the
belimumab group and 13 [93 %] patients assigned to the placebo group) received a transplant
and were included in the mITT population. These investigators observed similar proportions of
adverse events (AEs) in the belimumab and placebo groups, including serious infections (1 [8 %]
of 12 in the belimumab group and 5 [38 %] of 13 in the placebo group during the 6-month on-
treatment phase; and none in the belimumab group and 2 [15 %] in the placebo group during the
6-month follow-up). In the on-treatment phase, 1 patient in the placebo group died because of
fatal myocardial infarction (MI) and acute cardiac failure. The co-primary end-point of a reduction
Proprietary 15/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
in naive B cells from baseline to week 24 was not met. Treatment with belimumab did not
significantly reduce the number of naive B cells from baseline to week 24 (adjusted MD between
the belimumab and placebo treatment groups -34.4 cells/μL, 95 % CI: -109.5 to 40.7). The
authors concluded that belimumab might be a useful adjunct to standard-of-care
immunosuppression in renal transplantation, with no major increased risk of infection and
potential beneficial effects on humoral allo-immunity. These preliminary findings need to be
validated by well-designed studies.
Discoid Lupus
Chong et al (2014) stated that B-cell activating factor of the TNF family (BAFF) promotes the
maturation and survival of B cells. Because BAFF levels are elevated in systemic lupus
erythematosus (SLE) patients, BAFF has been the target of emerging therapies for SLE, such as
belimumab. Levels of BAFF and its receptors in discoid lupus erythematosus (DLE) patients are
unknown. These researchers compared skin and blood mRNA and protein levels of BAFF and
its receptors BAFF-R, TACI, and BCMA in DLE subjects with (DLE+/SLE+ (n = 28)) and without
SLE (DLE+/SLE- (n = 35)), psoriasis subjects (n = 11), and normal subjects (n = 42). They used
quantitative real-time PCR to measure blood and skin BAFF, BAFF-R, TACI, and BCMA mRNA,
sandwich ELISAs to measure sera BAFF, and immunohistochemistry to evaluate BAFF and
BAFF-R skin protein expression. BAFF mRNA and protein levels were highest in DLE+/SLE+
blood, followed by DLE+/SLE-, psoriasis, and normal blood. BAFF protein also correlated with
anti-nuclear antibodies, and auto-antibodies against double-stranded DNA, single-stranded DNA,
and ribonucleoprotein, and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
scores in DLE patients. While showing no difference between DLE+/SLE+ and DLE+/SLE- skin,
BAFF and its receptors mRNA were up-regulated in DLE skin versus normal and psoriasis skin;
DLE skin had higher percentages of BAFF-R⁺ inflammatory cells, likely T cells and
macrophages, than psoriasis and normal skin. The authors concluded that BAFF may be a
serologic marker of systemic disease in DLE patients; BAFF and its receptors were elevated in
DLE skin, suggesting that targeted therapies against these proteins could treat refractory DLE
patients.
Ugarte and colleagues (2018) evaluated the clinical response to combined therapy with
hydroxychloroquine and mepacrine in patients with SLE and refractory joint and/or skin disease.
Mepacrine was added to 46 SLE patients unresponsive to treatment with the following drug
combinations: hydroxychloroquine + prednisone + immunosuppressive drugs (n = 24),
hydroxychloroquine + prednisone (n = 16), hydroxychloroquine + prednisone + retinoids (n = 2),
hydroxychloroquine alone (n = 1), hydroxychloroquine + 1 immunosuppressive drug (n = 1),
hydroxychloroquine + prednisone + 1 immunosuppressive drug + belimumab (n = 1) or
hydroxychloroquine + prednisone + belimumab (n = 1). The outcome variable was the clinical
Proprietary 16/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
response, either complete or partial, based on clinical judgement. The Cutaneous Lupus
Erythematosus Disease Area and Severity Index (CLASI) and the SLEDAI score were
additionally used. A total of 91 % patients showed complete/partial response, with similar rates
among those with joint or skin disease. In patients with cutaneous activity, a statistically
significant decrease in the CLASI was seen. There also was a statistically significant decrease
in the SLEDAI. The mean daily dose of prednisone decreased from 5.8 to 3.4 mg/day (p = 0.001).
Prednisone could be discontinued in 20 % of patients. No serious adverse events (AEs)
were seen. Smoking was the only predictor of complete response. The authors concluded that
in the setting of refractory skin and/or joint disease, the addition of mepacrine to previous therapy
including hydroxychloroquine was safe and effective in reducing disease activity and decreasing
prednisone doses. The fact that smokers responded better opened the door to further studying
the combination of mepacrine-hydroxychloroquine as a 1st-line therapy in such patients.
(Discoid lupus was one of the keywords listed in the present study).
An UpToDate review on “Initial management of discoid lupus and subacute cutaneous lupus”
(Clarke, 2018a) does not mention belimumab as a therapeutic option. Furthermore, an
UpToDate review on “Management of refractory discoid lupus and subacute cutaneous lupus”
(Clarke, 2018b) states that “Multiple other medications have been used for subacute cutaneous
lupus erythematosus (SCLE) and discoid lupus erythematosus (DLE). With the exception of
clofazimine, data supporting these therapies [including belimumab] are limited … The effect of
belimumab in cutaneous LE has not been well studied; however, in a series of 5 patients with
SLE and acute cutaneous lupus erythematosus, SCLE, and/or DLE, all had significant
improvement in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)
disease activity scores with the addition of intravenous belimumab to standard treatment. The
average time to clinical improvement was 4 months, and marked improvement occurred as early
as 8 weeks. Serious potential adverse effects of belimumab include hypersensitivity reactions,
infections, and depression”.
Early Diffuse Cutaneous Systemic Sclerosis
In a randomized, double-blind, placebo-controlled, pilot trial, Gordon and colleagues (2018)
evaluated the safety and efficacy of treatment with belimumab in patients with early diffuse
cutaneous systemic sclerosis (dcSSc) treated with background mycophenolate mofetil (MMF).
In this 52-week, investigator-initiated, single-center, double-blind, placebo-controlled, pilot study,
a total of 20 patients with dcSSc recently started on MMF were randomized 1:1 to additionally
receive belimumab at 10 mg/kg intravenously or placebo. These investigators assessed safety,
efficacy, and differential gene expression. In the belimumab group, the median modified Rodnan
skin thickness score (MRSS) decreased from 27 (interquartile range [IQR] 26.5 to 31) to 18 (IQR
11 to 23) (p = 0.039). In the placebo group, the median MRSS decreased from 28 (IQR 22 to 28)
Proprietary 17/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
to 21 (IQR 14 to 25) (p = 0.023). The median change in MRSS was -10 (IQR -13 to -9) in the
belimumab group and -3.0 (IQR -15 to -1) in the placebo group (p = 0.411). There were no
significant differences between the groups in the number of AEs. A significant decrease in
expression of B cell signaling and pro-fibrotic genes and pathways was observed in patients with
improved MRSS in the belimumab group but not in the placebo group. The authors concluded
that patients in both treatment groups experienced significant improvements in MRSS. The
median difference was greater in the belimumab group but did not achieve statistical significance
in this small pilot study; AEs were similar between the groups. Changes in gene expression
were consistent with mechanism of action and showed that clinical response to treatment with
belimumab was associated with a significant decrease in pro-fibrotic genes and pathways.
These researchers stated that additional studies are needed to determine the role of belimumab
in the treatment of dcSSc.
Lupus Nephritis
Margiotta and colleagues (2018) stated that the treatment of lupus nephritis (LN) is an unmet
need in the management of patients with SLE. These investigators reported 2 cases of women
affected by LN (Society of Nephrology/Renal Pathology Society (ISN/RPS) Class IV) with
serological active disease, high disease activity and marked fatigue. In both cases, MMF, as
induction therapy, was poorly tolerated because of gastro-intestinal (GI) toxicity. Belimumab,
together with low-doses of MMF, was effective as induction treatment leading to early
achievement of complete renal response in these 2 selected cases of LN. The authors also
presented a literature review concerning the safety and efficacy of belimumab in LN. They
stated that further studies are needed to evaluate the use of belimumab to manage the renal
involvement in patients with SLE.
Systemic Sclerosis
Katsiar and colleagues (2018) noted that systemic sclerosis (SSc) is a chronic systemic disease
characterized by microvasculopathy, immune activation, and extensive collagen deposition.
Microvasculopathy and immune activation occur very early in the disease process. Evidence
from animal models and in-vitro studies indicated that T-cells and B-cells activate fibroblasts to
produce collagen. Traditional immuno-suppressants, cyclophosphamide(CyP),
methotrexate(MTX), and more recently mycophenolate mofetil (MMF), may prove more effective
if used very early in the disease course. These drugs showed some benefit in skin (MTX, CyP,
MMF) and lung function (CyP, MMF). Biologicals, such as intravenous immunoglobulin (IVIG),
belimumab (Beli), tocilizumab(TCZ), abatacept (Aba), rituximab (RTX) and fresolimumab (Fresu)
appeared promising as they exhibited some benefit in skin (IVIG, Beli, TCZ, Aba, RTX, Fresu),
Proprietary 18/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
hand function (IVIG), and joints (IVIG, TCZ, Aba). Autologous stem cell transplantation showed
the best therapeutic efficacy on skin and internal organs, and looks very promising, as
modification of transplantation immunosuppression is decreasing the early high mortality.
CPT Codes / HCPCS Codes / ICD-10 Codes
Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":
Code Code Description
Other CPT codes related to the CPB:
86038 Antinuclear antibodies (ANA)
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or
drug); initial, up to 1 hour
96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug);
subcutaneous or intramuscular
HCPCS codes covered if selection criteria are met:
J0490 Injection, Belimumab, 10 mg
Other HCPCS codes related to the CPB:
J0390 Injection, chloroquine hydrochloride
J0456 Injection, azithromycin, 500 mg
J1020 Injection, methylprednisolone acetate, 20 mg
J1030 Injection, methylprednisolone acetate, 40 mg
J1094 Injection, dexamethasone acetate, 1 mg
J1100 Injection, dexamethasone sodium phosphaste, 1 mg
J1700 Injection, hydrocortisone acetate, up to 25 mg
J1710 Injection, hydrocortisone sodium phosphate, up to 50 mg
J1720 Injection, hydrocortisone sodium succinate, up to 100 mg
J7312 Injection, dexamethasone, intravitreal implant, 0.1 mg
J7500 Azathioprine, oral, 50 mg
J7501 Azathioprine, parenteral, 100 mg
J7502 Cyclosporine, oral, 100 mg
J7509 Methylprednisolone oral, per 4 mg
Proprietary 19/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
Code Code Description
J7512 Prednisone, immediate release or delayed release, oral, 1 mg
J7515 Cyclosporine, oral, 25 mg
J7516 Cyclosporine, parenteral, 250 mg
J7517 Mycophenolate mofetil, oral, 250 mg
J7637 Dexamethasone, inhalation solution, compounded product, administered through
dme, concentrated form, per milligram
J7638 Dexamethasone, inhalation solution, compounded product, administered through
dme, unit dose form, per milligram
J8540 Dexamethasone, oral 0.25 mg
J8610 Methotrexate; oral, 0.25 mg
J9070 Cyclophosphamide, 100 mg [not covered when used in combination with Benlysta]
Q0144 Azithromycin dihydrate, oral, capsules/powder, 1 gram
ICD-10 codes covered if selection criteria are met:
M32.0 - M32.9 Systemic lupus erythematosus (SLE)
ICD-10 codes not covered for indications listed in the CPB :
C88.0 Waldenstrom macroglobulinemia
D68.61 Antiphospholipid syndrome
G35 Multiple sclerosis
G70.00 Myasthenia gravis without (acute) exacerbation
H20.00 - H21.9 Disorders of iris and ciliary body
H35.061 - H35.069 Retinal vasculitis
L40.50 - L40.59 Psoriatic arthritis
M05.00 - M06.9 Rheumatoid arthritis
M1A.00x+ - M10.9 Gout
M30.0 Polyarteritis nodosa [antibody-associated vasculitis]
M31.30 - M31.31 Wegener's granulomatosis [antibody-associated vasculitis]
M34.0 - M34.9 Systemic sclerosis
M35.00 - M35.09 Sicca syndrome [Sjögren]
N18.4 - N18.6 Chronic kidney disease, stage 4 (severe), stage 5, ESRD
T86.810 Lung transplant rejection [antibody-mediated rejection]
Z94.0 Kidney transplant status
Proprietary 20/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
Code Code Description
Z94.1 Heart transplant status
Z94.2 Lung transplant status
Z94.3 Heart and lungs transplant status
Z94.4 Liver transplant status
Z94.82 Intestine transplant status
Z94.83 Pancreas transplant status
Z94.84 Stem cells transplant status
Z99.2 Dependence on renal dialysis
1. Finnish Medical Society Duodecim. Systemic lupus erythematosus (SLE). In: EBM
Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience.
John Wiley & Sons; February 20, 2007.
2. Furie R, Stohl W, Ginzler EM, et al; Belimumab Study Group. Biologic activity and safety
of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal
antibody: A phase I trial in patients with systemic lupus erythematosus. Arthritis Res
Ther. 2008;10(5):R109.
3. Aran AA, Putterman C. Treatment of lupus nephritis: Facing the era of immunotherapy.
Panminerva Med. 2008;50(3):235-245.
4. Hawker K. B-cell-targeted treatment for multiple sclerosis: Mechanism of action and
clinical data. Curr Opin Neurol. 2008;21 Suppl 1:S19-S25.
5. Bingham CO 3rd. Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp Jt Dis.
2008;66(3):210-215.
6. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-
controlled, dose-ranging study of belimumab in patients with active systemic lupus
erythematosus. Arthritis Rheum. 2009;61(9):1168-1178.
7. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells
in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-
controlled, dose-ranging study. Arthritis Rheum. 2010;62(1):201-210.
8. No authors listed. Belimumab: Anti-BLyS monoclonal antibody; Benlysta; BmAb;
LymphoStat-B. Drugs R D. 2010;10(1):55-65.
Proprietary 21/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
9. Navarra SV, Guzmán RM, Gallacher AE, et al; BLISS-52 Study Group. Efficacy and safety
of belimumab in patients with active systemic lupus erythematosus: A randomised,
placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731.
10. U.S. Food and Drug Administration (FDA). FDA approves Benlysta to treat lupus. Press
Release. Silver Spring, MD: FDA; March 11, 2011.
11. Phung OJ. Belimumab: A B-lymphocyte stimulator inhibitor for systemic lupus
erythematosus. Formulary. 2011;46(4):118, 127-129.
12. GlaxoSmithKline(GSK).Benlysta (belimumab).PrescribingInformation.Research
Triangle Park, NC: GSK; March 2011,
13. Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: Issues in
perspective. Transplantation. 2011;91(10):1057-1064.
14. Di W, Chang Y, Wu YJ, Wei W. Research progress on B cell surface molecules targeted
therapy in rheumatoid arthritis. Sheng Li Ke Xue Jin Zhan. 2011;42(3):175-180.
15. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology
guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care
Res (Hoboken) 2012;64(6):797-808.
16. Khattri S, Zandman-Goddard G, Peeva E. B-cell directed therapies in antiphospholipid
antibody syndrome - New directions based on murine and human data. Autoimmun
Rev. 2012;11(10):717-722.
17. Diaz-Manera J, Rojas García R, Illa I. Treatment strategies for myasthenia gravis: An
update. Expert Opin Pharmacother. 2012;13(13):1873-1883.
18. O'Neill I, Scully C. Biologics in oral medicine: Sjogren syndrome. Oral Dis.
2013;19(2):121-127.
19. Jin X, Ding C. Belimumab -- an anti-BLyS human monoclonal antibody for rheumatoid
arthritis. Expert Opin Biol Ther. 2013;13(2):315-322.
20. Bishton M, Spencer A, Dickinson M, Ritchie D. A single-arm, phase II study of the anti-
Blys monoclonal antibody belimumab in symptomatic Waldenstrom
macroglobulinemia. Clin Lymphoma Myeloma Leuk.2013;13(5):575-578.
21. Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary
Sjogren's syndrome: Results of the BELISS open-label phase II study. Ann Rheum Dis.
2015;74(3):526-531.
22. Furuta S, Jayne D. Emerging therapies in antineutrophil cytoplasm antibody-associated
vasculitis. Curr Opin Rheumatol. 2014;26(1):1-6.
23. De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by
rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and
overexpession of BAFF: Evidence for long-term efficacy. Clin Exp Rheumatol.
2014;32(4):490-494.
24. Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus
nephritis. Curr Opin Rheumatol. 2014;26(5):502-509.
Proprietary 22/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
25. Lin P, Suhler EB, Rosenbaum JT. The future of uveitis treatment. Ophthalmology.
2014;121(1):365-376.
26. Rosenbaum JT. Uveitis: Treatment. UpToDate [serial online]. Waltham, MA:
UpToDate; reviewed July 2014.
27. Selmi C, Generali E, Massarotti M, et al. New treatments for inflammatory rheumatic
disease. Immunol Res. 2014;60(2-3):277-288.
28. De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12
months in primary Sjogren's syndrome: The BELISS open-label phase II study.
Rheumatology (Oxford). 2015;54(12):2249-2256.
29. Boumpass DR, Fessler BJ, Austin HA, et al. Systemic lupus erythematosus: Emerging
concepts. Ann Int Med 1995;123:42‐53.
30. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence‐based systemic lupus
erythematosus responder index. Arthritis Rheum. 2009;61(9):1143‐1151.
31. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and
other rheumatic conditions in the United States: Part I. Arthritis Rheum 2008;58:15‐25.
32. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and
other rheumatic conditions in the United States: Part II. Arthritis Rheum 2008;58:26‐35.
33. Sacks JJ, Helmick CG, Langmaid G, Sniezek JE. Trends in deaths from systemic lupus
erythematosus –United States, 1979‐1998. MMWR 2002;51:371‐374.
34. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of
systemic lupus erythematosus. Arthritis Rheum 1982;25:1271‐1277.
35. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double‐blind, placebo-
controlled, dose‐ranging study of belimumab in patients with active systemic lupus
erythematosus. Arthritis Rheum. 2009;61(9):1168‐1178.
36. De Scheerder MA, Boey O, Mahieu E, et al. Case report: Successful treatment of
membranous lupus nephritis with belimumab in an African female immigrant. Clin
Rheumatol. 2016;35(6):1649-1653.
37. Vashisht P, Borghoff K, O'Dell JR, Hearth-Holmes M. Belimumab for the treatment of
recalcitrant cutaneous lupus. Lupus. 2017;26(8):857-864.
38. Letaief H, Lukas C, Barnetche T, et al. Efficacy and safety of biological DMARDs
modulating B cells in primary Sjögren's syndrome: Systematic review and meta-
analysis. Joint Bone Spine. 2018;85(1):15-22.
39. GlaxoSmithKline (GSK). Benlysta (belimumab) for injection, for subcutaneous use.
Prescribing Information. BNL:8PI. Research Triangle Park, NC: GSK; revised July 2017.
40. GlaxoSmithKline (GSK) GSK receives FDA approval for a new self-injectable formulation
of Benlysta (belimumab) for systemic lupus erythematosus. News Release. Research
Triangle Park, NC: GSK; July 21, 2017.
41. Chong BF, Tseng LC, Kim A, et al. Differential expression of BAFF and its receptors in
discoid lupus erythematosus patients. J Dermatol Sci. 2014;73(3):216-224.
Proprietary 23/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
42. Becvar R. Novel trends in monitoring and therapy of ANCA associated vasculitides.
Vnitr Lek. 2018;64(2):164-168.
43. Banham GD, Flint SM, Torpey N, et al. Belimumab in kidney transplantation: An
experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet.
2018;391(10140):2619-2630.
44. Clarke J. Initial management of discoid lupus and subacute cutaneous lupus. UpToDate
[online serial]. Waltham, MA: UpToDate; reviewed July 2018a.
45. Clarke J. Management of refractory discoid lupus and subacute cutaneous lupus.
UpToDate [online serial]. Waltham, MA: UpToDate; reviewed July 2018b.
46. Hewett K, Sanders DB, Grove RA, et al; BEL115123 Study Group. Randomized study of
adjunctive belimumab in participants with generalized myasthenia gravis. Neurology.
2018;90(16):e1425-e1434.
47. Hulbert AL, Pavlisko EN, Palmer SM. Current challenges and opportunities in the
management of antibody-mediated rejection in lung transplantation. Curr Opin Organ
Transplant. 2018;23(3):308-315.
48. Gordon JK, Martyanov V, Franks JM, et al. Belimumab for the treatment of early diffuse
systemic sclerosis: Results of a randomized, double-blind, placebo-controlled, pilot
trial. Arthritis Rheumatol. 2018;70(2):308-316.
49. Margiotta DPE, Basta F, Batani V, Afeltra A. Belimumab and low-doses of
mycophenolate mofetil as induction therapy of class IV lupus nephritis: Case series and
literature review. BMC Nephrol. 2018;19(1):54.
50. Ugarte A, Porta S, Ríos R, et al. Combined mepacrine-hydroxychloroquine treatment in
patients with systemic lupus erythematosus and refractory cutaneous and articular
activity. Lupus. 2018;27(10):1718-1722.
51. Dobrowolski C, Erkan D. Treatment of antiphospholipid syndrome beyond
anticoagulation. Clin Immunol. 2018 Mar 3 [Epub ahead of print].
52. Katsiari CG, Simopoulou T, Alexiou I, Sakkas LI. Immunotherapy of systemic sclerosis.
Hum Vaccin Immunother. 2018;14(11):2559-2567.
53. GlaxoSmithKline (GSK). Benlysta (belimumab). Prescribing Information. Reference ID:
4424920. Research Triangle Park, NC: GSK; revised April2019.
54. Banham GD, Flint SM, Torpey N, et al. Belimumab in kidney transplantation: An
experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet.
2018;391(10140):2619-2630.
55. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology
Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1)1
26.
56. CVS Caremark. Clinical Consult. CVS Caremark Clinical Programs Review. Focus on
Rheumatology Clinical Programs. Woonsocket, RI: CVS Health; March 2012.
Proprietary 24/25
Belimumab (Benlysta) - Medical Clinical Policy Bulletins | Aetna
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and
constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or
program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any
results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna
or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be
updated and therefore is subject to change.
Copyright © 2001-2019 Aetna Inc.
Proprietary 25/25
AETNA BETTER HEALTH® OF PENNSYLVANIA
Amendment to Aetna Clinical Policy Bulletin Number: 0818
Belimumab (Benlysta)
There are no amendments for Medicaid.
www.aetnabetterhealth.com/pennsylvania revised 11/12/2019
Proprietary